Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor with SoC in Newly Diagnosed or Recurrent Glioblastoma
NCT04421378Phase 2Terminated
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Jun 2020
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of selinexor in glioblastoma (GBM), sponsored by Karyopharm Therapeutics Inc.. Started Jun 2020; status: terminated.
02
Drugs
selinexor
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04421378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04421378.